Karyopharm Therapeutics Received Notice of Delisting

What happened

Nasdaq notified Karyopharm Therapeutics on November 4, 2026, that it will delist the company’s securities following its Chapter 11 bankruptcy filing. The company will not appeal, and trading is scheduled to be suspended on November 11, after which the stock is expected to trade over the counter as KPTIQ.

Confirmed

Global impact / market context

The planned delisting and bankruptcy plan put existing shareholders at risk of losing their entire investment: the plan provides no distribution to common or preferred stockholders, and the company expects those securities to have no value. Over-the-counter trading would not change that stated expectation.

Analyst inference

This is a company-specific bankruptcy and delisting event, not evidence of broader market weakness. Suspension from Nasdaq would move expected trading to the over-the-counter market, where investors may face a different trading venue, while the bankruptcy plan leaves no stated recovery for existing shareholders.

Analyst inference

What to watch

1. The scheduled November 11 trading suspension is the next stated event; if it proceeds, Nasdaq trading ends and the stock is expected to trade over the counter as KPTIQ. Confirmed
2. The bankruptcy plan states that common and preferred stockholders receive no distribution. Any change to that plan could alter expected recovery, but no change is stated here. Confirmed
3. Whether the stock begins over-the-counter trading under KPTIQ remains to be seen; the article describes this as expected, not as a completed transition. Analyst inference

Evidence

• Original source link unavailable